3SBio Pays $6.25 Million for Gout Treatment

3SBio Inc. acquired worldwide rights to a clinical-stage treatment for gout from EnzymeRx of New Jersey for $6.25 million. In a pair of Phase I trials, Pegsiticase (Uricase-PEG 20), a pegylated recombinant uricase, proved effective against gout in all patients. 3SBio plans to develop the drug for use in China, while out-licensing the drug to partners for development elsewhere in the world. More details.... Stock Symbol: (NSDQ: SSRX)